News

Good news! Dr. Tong Wang, CSO of Centec and Dr. Jiahong Zhao, CMO of Centec were awarded as Gusu Leading Talents

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2021-12-24
  • Views:0

(Summary description)Suzhou, China, December 23, 2021 - Dr. Tong Wang, CSO (Chief Scientific Officer) and Dr. Jiahong Zhao, CMO (Chief Medical Officer) of CGeneTech have been selected as the second batch of Gusu Leaders in Suzhou City for the year 2021.

Good news! Dr. Tong Wang, CSO of Centec and Dr. Jiahong Zhao, CMO of Centec were awarded as Gusu Leading Talents

(Summary description)Suzhou, China, December 23, 2021 - Dr. Tong Wang, CSO (Chief Scientific Officer) and Dr. Jiahong Zhao, CMO (Chief Medical Officer) of CGeneTech have been selected as the second batch of Gusu Leaders in Suzhou City for the year 2021.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2021-12-24
  • Views:0

Suzhou, China, December 23, 2021 - Dr. Tong Wang, CSO (Chief Scientific Officer) and Dr. Jiahong Zhao, CMO (Chief Medical Officer) of CGeneTech have been selected as the second batch of Gusu Leaders in Suzhou City for the year 2021.

Dr. Tong Wang received his bachelor's degree in chemistry from Peking University and his PhD in chemistry from Syracuse University. Dr. Wang has more than 20 years of experience in full chain drug development and management in top pharmaceutical companies and research institutes in the US. Prior to joining CGeneTech, Dr. Wang worked at Schering-Plough and Translational Genomics Institute/Translational Drug Development, where he led nearly ten world-first small molecule drug development projects in the medical fields of cancer, immunology, ophthalmology and metabolism, and successfully advanced four new drug projects to the clinical stage.

1

Dr. Tong Wang, CSO (Chief Scientific Officer) of CGeneTech

Dr. Tong Wang has been awarded the Suzhou Park Innovation and Technology Leader A Class Talent, High-end Foreign Expert Introduction Program, and Senior Engineer, and has obtained nearly 20 invention patents and published more than 10 academic papers.

Dr. Jiahong Zhao is a medical doctor from Fudan University School of Medicine, with more than 20 years of professional and team management experience in drug clinical trials, 6 years of work experience as a hematologist in clinical internal medicine and teaching experience in medical school. Before joining CGeneTech, he worked as Vice President and CMO of a large CRO company, responsible for more than 600 clinical practical projects, presided over the clinical development of 3 new varieties of blood products successfully marketed, wrote 7 varieties of drug instructions selected by the State Pharmacopoeia Commission, which became the standard version of the blood products industry and used to date, participated in the State Drug Administration and CDE organization as an external expert As an external expert, he participated in the "7.22 data verification work" and the drafting and revision of many technical guidelines organized by the State Drug Administration and CDE.

1

Dr. Jiahong Zhao, CMO (Chief Medical Officer) of CGeneTech

Dr. Jiahong Zhao has been awarded more than ten honorary titles such as special professor of Jiangsu University and Zhejiang University of Traditional Chinese Medicine, external reviewer of CDE Professional Committee on Blood Products, special editorial board member and reviewer of Zhongnan Pharmacology, member of Professional Committee on Research and Evaluation of Traditional Chinese Medicine Injectables, reviewer of pharmaceutical projects of Ministry of Science and Technology of China, Shanghai Science and Technology Commission and Shanghai Health and Health Commission.

The

The listing application of Shengshi Tyco's new hypoglycemic drug Shenggliptin was accepted

Today, Shengshi Tyco has accepted the marketing application (NDA) of Shenggliptin, a DPP-4 inhibitor, submitted to the National Drug Administration (NMPA) for the treatment of type 2 diabetes.
2023-02-02
Quantity

"Quantity" Half Achieves Double Prosperity: Tyco's Class 1 New Hypoglycemic Drug Shenggliptin Uncovers Blindness Data

Today, Shengshi Tyco has completed a key clinical study on a class 1 new hypoglycemic drug under development: phase III clinical trial of DPP-4 inhibitor shenggliptin in the treatment of type 2 diabetes. A dose of 50mg can reach the preset end point of the trial. A therapeutic dose of "half the dose" will further improve the safety of this drug and is expected to become the best hypoglycemic drug in the same class.
2022-10-17

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO